article thumbnail

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Under the deal, both companies will partner on the research and preclinical studies, which will be funded by Moderna.

article thumbnail

Gene editing: beyond the hype

pharmaphorum

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers. That would just slow the whole field down.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3rd In Vivo Cell Engineering & Gene Editing Summit

pharmaphorum

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

In-Vivo 52
article thumbnail

Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline

Bio Pharma Dive

The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research.

article thumbnail

Researchers develop CRISPR-based drug candidate for microbiome targeting

Pharmaceutical Technology

The research team has designed four bacterial viruses which use CRISPR technology to kill the unwanted bacteria precisely. The team then engineered the phages through gene editing to improve their targeting ability. SNIPR001 also reduced the number of E coli more than naturally occurring phages.

article thumbnail

AstraZeneca pays record 660% premium for gene editing company LogicBio

pharmaphorum

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The post AstraZeneca pays record 660% premium for gene editing company LogicBio appeared first on.

article thumbnail

#news #biotech Researchers develop an engineered ‘mini’ CRISPR genome editing system

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers develop an engineered ‘mini’ CRISPR genome editing system.The common analogy for CRISPR gene editing is that it works like molecular scissors, cutting out select sections of … Continue reading → (..)